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Abstract
The disposition of fexofenadine, a commonly-used antihistamine drug, is governed primarily by
active transport. Biliary excretion of the parent compound is the major route of systemic clearance.
Previous studies demonstrated that fexofenadine hepatic uptake is mediated by organic anion
transporting polypeptides. Recently, we showed that in mice fexofenadine is excreted into bile
primarily by Mrp2 (Abcc2). In the present study, the role of Mrp3 (Abcc3) and Mrp4 (Abcc4) in the
hepatobiliary disposition of fexofenadine was examined in knockout mice using in situ liver
perfusion. Compared to wild-type mice, basolateral excretion of fexofenadine was impaired resulting
in a ~50% decrease in perfusate recovery in Abcc3  ( − / − ) mice; in contrast, fexofenadine
hepatobiliary disposition was unaltered in Abcc4 ( − / − ) mice. As expected, in Abcc2 ( − / − ) mice,
fexofenadine was redirected from the canalicular to the basolateral membrane for excretion. In
Abcc2 ( − / − )/Abcc3 ( − / − ) double knock-out mice, fexofenadine biliary excretion was impaired,
but perfusate recovery was similar to wild-type mice, and more than 2-fold higher than in
Abcc3  ( − / − ) mice, presumably due to compensatory basolateral transport mechanism(s). These
results demonstrate that multiple transport proteins are involved in the hepatobiliary disposition of
fexofenadine. In addition to Mrp2 and Mrp3, other transport proteins play an important role in the
biliary and hepatic basolateral excretion of this zwitterionic drug.
Introduction
Fexofenadine is an H1 receptor antagonist commonly used in the treatment of seasonal allergies
and chronic urticaria. The intestinal absorption of fexofenadine is mediated by organic anion
transporting polypeptides (Oatps), a process that is counteracted by P-glycoprotein-mediated
efflux (Cvetkovic et al., 1999). Metabolism accounts for less than 5% of total fexofenadine
clearance in humans, and the oral and intravenous exposure of fexofenadine in rats is not altered
by the pan-cytochrome P450 mechanism-based inactivator, aminobenzotriazole (Strelevitz et
al., 2005). However, specific information regarding fexofenadine metabolism in mice is not
available. Biliary excretion of unchanged fexofenadine is the primary route of systemic
clearance (Tahara et al., 2005). Although fexofenadine intestinal absorption and blood-brain
barrier penetration are limited by P-glycoprotein (Cvetkovic et al., 1999; Tahara et al., 2005),
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the biliary excretion of fexofenadine is mediated by multiple transport mechanisms (Tian et
al., 2008). The unusual dispositional properties of fexofenadine, i.e. low metabolism and
extensive transport, have led to its use as a probe for the analysis of both Oatp and P-
glycoprotein modulation by various co-administered drugs and herbal products (Banfield et
al., 2002; Zhou et al., 2004; Shon et al., 2005; Lemma et al., 2006).
Following uptake from sinusoidal blood into the hepatocyte, drugs and derived metabolites,
may undergo excretion across the canalicular membrane into bile or across the basolateral
membrane into blood. For example, carboxydichlorofluorescein is taken up into hepatocytes
via basolateral Oatps, and is subsequently excreted unchanged into bile by multidrug
resistance-associated protein (Mrp) 2 and also undergoes basolateral export into blood by Mrp3
(Zamek-Gliszczynski et al., 2003; Nezasa et al., 2006). Similarly, glucuronide conjugates of
acetaminophen and morphine also are subject to bidirectional excretion into bile and blood by
Mrp2 and Mrp3, respectively (Xiong 2000, 2002, van de Wetering 2007, Zelcer 2005).
Basolateral Mrp3 is similar to canalicular Mrp2 in terms of amino acid sequence, membrane
topology, and substrate specificity (Konig et al., 1999; Ogawa et al., 2000). Mrp3 is highly
upregulated in obstructive cholestasis (e.g. bile duct ligation) and hereditary conjugated
hyperbilirubinemia in rats and humans (e.g. Mrp2-deficient animals, Dubin-Johnson patients),
acting as an overflow pump for hepatic excretion of Mrp2 substrates and conjugated bile acids
when biliary excretion is impaired (Hirohashi et al., 1998; Konig 1999). Although expression
levels of Mrp3 protein are relatively high in mice, a 2-fold up-regulation of Mrp3 protein is
still observed in Mrp2-knockout mice (Nezasa et al., 2005). Based upon recent findings that
the biliary excretion of fexofenadine is mediated in part by Mrp2 in mice (Tian et al., 2008),
we hypothesized that fexofenadine may also undergo hepatic basolateral excretion via Mrp3.
In addition to Mrp3, Mrp4 functions as an excretory mechanism on the hepatic basolateral
membrane (Rius et al., 2003). Limited evidence of functional overlap between Mrp3 and Mrp4
exists. For example, both Mrp3 and Mrp4 are upregulated in response to obstructive cholestasis
(Hirohashi et al., 1998; Denk et al., 2004). Furthermore, both Mrp3 and Mrp4 mediate the
hepatic basolateral excretion of the sulfate metabolites of acetaminophen, 4-
methylumbelliferone, and harmol in mice (Zamek-Gliszczynski et al., 2006). While these
features suggest that Mrp3 and Mrp4 may be involved in the hepatic basolateral excretion of
fexofenadine, the extent to which these pumps function in this capacity has not been
investigated.
Studies outlined in this manuscript tested the hypothesis that fexofenadine undergoes
basolateral excretion from the liver via Mrp3 and Mrp4. Perfused livers from relevant
transporter-gene knockout mice were utilized to examine the role of Mrp2, Mrp3 and Mrp4 in
the hepatobiliary disposition of fexofenadine. Furthermore, the combined role of Mrp2 and
Mrp3 in the overall hepatic excretion of this zwitterion was studied in livers from
Abcc2  ( − / − )/Abcc3 ( − / − ) double-knockout mice. The data presented herein demonstrate
the importance of Mrp2 and Mrp3 in the biliary and hepatic basolateral excretion, respectively,
of fexofenadine in mice.
Material and Methods
Chemicals
Fexofenadine, cetirizine, taurocholate, and Krebs-Henseleit buffer packets were purchased
from Sigma Chemical Co. (St. Louis, MO). All other chemicals were of reagent grade and were
readily available from commercial sources.
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Male C57BL/6 wild-type (WT) (age-matched heterozygotes),
Abcc2 ( − / − ),Abcc3  ( − / − ), Abcc2 ( − / − )/Abcc3 ( − / − ), and Abcc4 ( − / − ) mice (23–
31g) were generated as described previously (Belinsky et al., 2005; Belinsky et al., 2007).
Abcc2 ( − / − ) mice have been generated recently by gene− targeting methods in the laboratory
of Dr. Gary Kruh (unpublished). Abcc2 ( − / − ), Abcc3 ( − / − ) and Abcc4 ( − / − ) mice
employed in this study were derived from mixed 129/C57BL/6 animals and were backcrossed
to C57BL/6 for eight generations. Abcc2 ( − / − ) and Abcc3  ( − / − ) mice on the C57BL/6
background were used to breed the Abcc2 ( − / − )/Abcc3 ( − / − ) mice. Mice were maintained
on a 12-h light/dark cycle with free access to water and rodent chow. Experiments were
performed at Fox Chase Cancer Center and approved by their Institutional Animal Care and
Use Committee.
In Situ Liver Perfusion
All experimental procedures were performed under full anesthesia induced with ketamine/
xylazine (140/8 mg/kg i.p.). The liver perfusion procedure was modified slightly from the
previous report of Tian et al (2007). Briefly, the common bile duct was ligated above the
duodenum to prevent bile from entering the intestine, and the gallbladder was cannulated with
PE-10 tubing (Becton Dickinson, Parsippany, NJ). The portal vein was cannulated with a 20-
gauge catheter (B. Braun Medical Inc., Bethlehem, PA), the abdominal vena cava below the
liver was severed immediately by incision, and the inferior vena cava above the liver was
cannulated with a 20-gauge catheter. The liver was perfused (5 ml/min with fexofenadine-free
continually oxygenated Krebs-Henseleit buffer containing 5 hM taurocholate) for an
equilibration period of approximately 15 min. Subsequently, the inferior vena cava was ligated
between the liver and kidney to direct all perfusate outflow through the cannulated inferior
vena cava above the liver. Following the pre-perfusion period to allow for equilibration of
temperature and bile flow, the liver was perfused for 30 min with buffer containing 0.5 hM
fexofenadine, followed by a washout with fexofenadine-free buffer for 45 min. Bile was
collected in 7-min intervals; outflow perfusate was collected at designated time points in
toto. Perfusion pressure and bile flow were monitored to assess liver viability (Chandra et al.,
2005).
Analytical Methods
Bile and outflow perfusate samples were analyzed by liquid chromatography with detection
by tandem mass spectrometry (Applied Biosystems API 4000 triple quadrupole with
TurboIonSpray interface, MDS Sciex, Concord, ON, Canada). Fexofenadine and cetirizine
(internal standard) were eluted from an Aquasil C18 column (5μm, 50mm × 2.1mm, Thermo-
Electron, Waltham, MA) using a mobile phase gradient (A: 0.1% formic acid in water, B: 0.1%
formic acid in methanol); 0–0.8 min hold at 10% B, 0.8–3.5 min linear increase to 85% B, 3.5–
4.0 min hold at 85% B, 4.0–4.5 min return to 10% B, 4.5–5 min hold at 10% B; flow rate was
0.75 mL/min (Shimazdu solvent delivery system, Columbia, MD). Fexofenadine and the
internal standard, cetirizine, were detected in positive ion mode using multiple reaction
monitoring: fexofenadine: 502.3 → 466.4 m/z, cetirizine: 389.0 → 201.0 m/z. Fexofenadine
was quantified with standard curves prepared in the appropriate matrix.
Data Analysis
All data were reported as mean ± SD (n = 3–4, per group). Statistical significance was assessed
by one-way analysis of variance (ANOVA) with Tukey’s post-hoc test. In cases where the
normality test failed, data were log-transformed prior to statistical analysis. In all cases, p <
0.05 was considered to be statistically significant.
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Body weight, liver weight, and bile flow
Body weight was comparable between WT and knockout mice (Table 1). Liver weight
(normalized for body weight) was significantly increased (~30%) in Abcc2 ( − / − ) and (~46%)
in Abcc2 ( − / − )/Abcc3 ( − / − ) relative to WT mice. Abcc3  ( − / − ) and Abcc4 ( − / − )
mouse liver weights were comparable to WT controls (Table 1). The bile flow rate was
decreased ~30% in Abcc2 ( − / − ) and Abcc2 ( − / − )/Abcc3 ( − / − ) mouse livers relative to
WT, but was normal in livers from Abcc3 ( − / − ) and Abcc4 ( − / − ) mice (Table 1).
Recovery of fexofenadine in outflow perfusate
Fexofenadine concentrations in outflow perfusate from WT and knockout mouse livers are
presented in Figure 1. For clarity, only mean data are plotted; standard deviations were within
~50% of the mean data. The total recovery of fexofenadine at the end of the washout period
as a percentage of the infused dose was 73 ± 10% in WT, 62 ± 30% in Abcc3 ( − / − ), 68 ±
9% in Abcc4 ( − / − ), 77 ± 12% in Abcc2 ( − / − ), and 71 ± 15% in Abcc2 ( − / − )/
Abcc3 ( − / − ) mouse livers. In order to quantify the impact of Mrp3 and Mrp4 genetic ablation
on the basolateral efflux of fexofenadine from the liver, fexofenadine recovery in perfusate
during the washout phase was expressed as a percentage of liver fexofenadine content at the
end of the infusion (determined as the difference between infused dose and the cumulative
mass of fexofenadine excreted in outflow perfusate and bile through 30 min; Table 2). The
fraction of fexofenadine excreted into outflow perfusate was significantly decreased (~50%)
in livers from Abcc3 ( − / − ) mice; in contrast, significantly increased perfusate recovery
(~60%) was noted in Abcc2 ( − / − ) relative to WT mouse livers. Interestingly, perfusate
recovery of fexofenadine in livers from Abcc2 ( − / − )/Abcc3 ( − / − ) mice was similar to WT
control livers. In contrast to livers from Abcc3 ( − / − ) mice, perfusate recovery of fexofenadine
in livers from Abcc4 ( − / − ) mice was unchanged.
Recovery of fexofenadine in bile
Fexofenadine biliary excretion rates and cumulative biliary excretion in livers from WT and
knockout mice are presented in Figures 2A and B, respectively; standard deviations were within
~50% of the mean data and are not included in the figures for clarity. The biliary recovery of
fexofenadine was not significantly different in Abcc3 ( − / − ) and Abcc4 ( − / − ) mouse livers
relative to WT controls (Figure 2B; Table 2). Fexofenadine biliary excretion rates and
cumulative biliary excretion were significantly decreased in livers from Abcc2 ( − / − ) and
Abcc2 ( − / − )/Abcc3 ( − / − ) mice (Figure 2). The biliary recovery of fexofenadine during the
washout phase, normalized for liver content of fexofenadine at the end of the infusion, was
~61% and ~53% lower in Abcc2 ( − / − ) and Abcc2 ( − / − )/Abcc3 ( − / − ) relative to WT
mouse livers, respectively (Table 2). Interestingly, liver fexofenadine concentrations at the end
of the washout period were not altered in Abcc3 ( − / − ), Abcc4 ( − / − ) and Abcc2 ( − / − )/
Abcc3 ( − / − ) mice (Table 2). However, consistent with our previous report (Tian et al.,
2008), liver fexofenadine concentrations decreased ~2-fold in Abcc2 ( − / − ) mice after the
washout phase (Table 2).
Discussion
Previous studies utilizing transporter gene knockout mice identified Mrp2 as the predominant
protein responsible for fexofenadine biliary excretion (Tian et al., 2008). In contrast,
fexofenadine biliary excretion was not impaired in mice lacking the breast cancer resistance
protein or P-glycoprotein (Tahara et al., 2005). In agreement with previous work, Mrp2 was
responsible for ~60% of fexofenadine biliary excretion in the current study. However, the
present data also establish the importance of Mrp3 in the hepatic basolateral excretion of
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fexofenadine. Approximately 50% of fexofenadine basolateral excretion may be attributed to
Mrp3-mediated transport when outflow perfusate concentrations are in the range of 300 ng/ml
based on the 2-fold decrease in perfusate recovery of fexofenadine in livers from
Abcc3 ( − / − ) mice. These data highlight the functional interplay between Mrp2 and Mrp3
in fexofenadine hepatobiliary disposition. However, the basolateral excretion of fexofenadine
in Abcc2 ( − / − )/Abcc3 ( − / − ) mice was not impaired. Fexofenadine concentrations in
Abcc3 ( − / − ) and Abcc2 ( − / − )/Abcc3 ( − / − ) mouse livers were similar to those in WT
mouse livers. Mechanism(s) responsible for the Mrp2- and Mrp3-independent component of
fexofenadine hepatobiliary clearance remain to be elucidated.
Mrp2 plays a critical role as an organic anion excretory system in liver detoxification. Unlike
human MRP3, MRP2 protein is highly expressed in humans under normal conditions (Stöckel
et al., 2000). Protein expression of Mrp3, the“Mrp2 backup system”, is increased markedly in
rats and humans that are deficient in Mrp2 (Hirohashi et al., 1998; Konig et al., 1999; Xiong
et al., 2002). Mrp3 constitutive expression levels in mice are already high, but in Mrp2-
knockout mice, Mrp3 is further upregulated (Nezasa et al., 2006). In contrast, this functional
compensation is not reciprocal in mouse liver; the absence of Mrp3 does not result in a notable
upregulation of Mrp2 protein or function in mouse liver, as demonstrated by this and other
studies (Belinsky et al., 2005; Zamek-Gliszczynski et al., 2006). This suggests that hepatic
protection mechanisms other than Mrp2-mediated biliary excretion exist in mice when Mrp3
function is ablated. Mrp4 is another efflux transport protein located on the hepatic basolateral
membrane (Rius et al., 2003). Limited evidence of functional overlap between Mrp3 and Mrp4
(Hirohashi et al 1999; Denk et al., 2004; Zamek-Gliszczynski et al., 2006) prompted the
exploration of fexofenadine disposition in livers from Abcc4 ( − / − ) mice. Interestingly,
fexofenadine basolateral excretion was not affected by the absence of Mrp4. The impact of
genetic ablation of Mrp4 has been associated with impaired Sulfotransferase 2a1 expression
and function (Assem et al., 2004), but an appreciable effect on the function or expression of
other hepatic transport proteins has not been observed (Assem et al., 2004; Mennone et al.,
2006; Zamek-Gliszczynski et al., 2006). Whether Mrp4 serves as the backup system for Mrp3-
mediated fexofenadine basolateral excretion requires further investigation.
The existence of multiple transport and backup transport systems on both the basolateral and
canalicular membranes complicates the extrapolation of transport studies from single-knockout
to double-knockout animals (van de Wetering et al., 2007). The biliary and basolateral
excretion of the Mrp2 and Mrp3 substrate, morphine-3-glucuronide in Abcc2 ( − / − )/
Abcc3 ( − / − ) mice following morphine administration was severely impaired, resulting in
considerable hepatic accumulation of the glucuronide metabolite. However, residual plasma
concentrations of morphine-3-glucuronide in Abcc2 ( − / − )/Abcc3( − / − ) mice were
substantial, and the concentrations of morphine-3-glucuronide were similar between
Abcc2 ( − / − )/Abcc3 ( − / − ) and WT mice 24 hrs post morphine administration, which resulted
in near −normal urinary excretion of morphine-3-glucuronide, suggesting that a low-capacity
backup transport system was present for the basolateral excretion of morphine-3-glucuronide
into plasma in Abcc2 ( − / − )/Abcc3 ( − / − ) mice (van de Wetering et al., 2007). In the present
study, fexofenadine biliary excretion in livers from Abcc2 ( − / − )/Abcc3 ( − / − ) mice was
impaired to the same extent as in mice only lacking Mrp2; fexofenadine basolateral excretion
in livers from these double-knockout mice was similar to WT mice, and was more than two-
fold higher than in Mrp3 single-knockout mice. The unchanged liver concentrations of
fexofenadine in Abcc3 ( − / − ) mice, and considerable basolateral excretion of fexofenadine
in the livers of Abcc2 ( − / − )/Abcc3 ( − / − ) mice, are consistent with the hypothesis that
additional clearance mechanisms compensate for the loss of Mrp3 function. Basolateral Mrps
(other than Mrp3), the bidirectional organic anion transport proteins, or other basolateral export
proteins may contribute to increased basolateral clearance of fexofenadine in Abcc2 ( − / − )/
Abcc3 ( − / − ) mouse livers. The possibility of altered fexofenadine metabolism in
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Abcc3 ( − / − ) and Abcc2 ( − / − )/Abcc3 ( − / − ) mouse livers cannot be ruled out because
no detailed information on fexofenadine metabolism in mouse livers has been published.
In summary, fexofenadine is taken up into the hepatocyte and undergoes biliary as well as
basolateral excretion. Using perfused livers from relevant transporter gene knockout mice,
Mrp2 and Mrp3 were identified as important transport proteins mediating fexofenadine biliary
and hepatic basolateral excretion, respectively. Mrp4 did not appear to contribute to hepatic
basolateral excretion of this zwitterionic drug in the intact mouse liver in the presence of Mrp3
and/or Mrp2 proteins. Mechanism(s) responsible for the residual, Mrp2- and Mrp3-
independent, biliary and basolateral excretion of fexofenadine remain to be elucidated. Once
again, this study exemplified the importance of using physiologically relevant systems such
as the intact liver to evaluate the contributions of hepatic transport proteins in drug
pharmacokinetic studies.
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Fexofenadine concentrations in outflow perfusate from wild-type C57BL/6
(●),Abcc3 ( − / − ) (▵), Abcc4 ( − / − ) (▽ ), Abcc2 ( − / − ) (□), and Abcc2 ( − / − )/Abcc3
( − / −  (⋄) mouse livers (mean data are plotted; n = 3–4 per group). Livers were perfused (5
ml/min) with fexofenadine (0.5 μM) for 30 min followed by a 45-min washout phase.
Tian et al. Page 9













Tian et al. Page 10














Biliary excretion rate (A) and cumulative biliary excretion (B) of fexofenadine in perfused
livers from wild-type C57BL/6 (●), Abcc3 ( − / − ) (▵), Abcc4 ( − / − ) (▽), Abcc2 ( − / − )
(□), and Abcc2 ( − / − )/Abcc3( − / −  (⋄) mice (mean data are plotted; n = 3–4 per group). Livers
were perfused (5 ml/min) with fexofenadine (0.5 μM) for 30 min followed by a 45-min washout
phase.
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Table 1
Body weight, liver weight normalized for body weight, and bile flow rate in wild-type and transporter gene knockout
mice. Mean ± SD (n = 3–4 per group).
Mice Body Weight (g) Liver Weight/Body Weight Bile Flow Rate (μL/min/g liver)
Wild-Type 27.5 ± 1.4 0.041 ± 0.006 1.3 ± 0.3
Abcc3 ( − / − ) 27.9 ± 3.1 0.043 ± 0.001 1.3 ± 0.2
Abcc4 ( − / − ) 26.1 ± 2.4 0.041 ± 0.005 1.3 ± 0.4
Abcc2 ( − / − ) 29.4 ± 1.9 0.053 ± 0.001 * 0.87 ± 0.02 *
Abcc2 ( − / − )/Abcc3 ( − / − ) 27.7 ± 1.5 0.060 ± 0.002 * 0.85 ± 0.15 *
*
p< 0.05 knockout vs. wild type.
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Table 2
Recovery of fexofenadine in perfusate and bile during the washout phase of mouse liver perfusions, and liver
concentrations after the washout phase. Values are expressed as percentage of fexofenadine liver content after the 30-
min infusion. Mean ± SD (n = 3–4 per group).
Mice Biliary Recovery (% liver
content at 30 min)
Recovery in Perfusate (% liver
content at 30 min)
Liver Concentration (ng/g
liver)
Wild-Type 15.3 ± 3.8 25.8 ± 4.1 1500 ± 330
Abcc3 ( − / − ) 13.5 ± 6.1 12.7 ± 6.1* 1500 ± 500
Abcc4 ( − / − ) 12.3 ± 3.3 26.2 ± 7.6 1300 ± 420
Abcc2 ( − / − ) 5.9 ± 3.4* 42.0 ± 2.7 * 850 ± 400
Abcc2 ( − / − )/Abcc3 ( − / − ) 7.1 ± 2.9 * 28.6 ± 12.3 1600 ± 420
*
p< 0.05 knockout vs. wild type.
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